Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissueYoichi Imaizumi, Hideyuki Okano, Makoto Suematsu et al.|Molecular Brain|2012Cited by 392
Sept4, a Component of Presynaptic Scaffold and Lewy Bodies, Is Required for the Suppression of α-Synuclein NeurotoxicityMasafumi Ihara, Makoto Kinoshita, Nobuyuki Yamasaki et al.|Neuron|2007Cited by 166
Pilot study of H<sub>2</sub> therapy in Parkinson's disease: A randomized double‐blind placebo‐controlled trialAsako Yoritaka, Nobutaka Hattori, Masashi Takanashi et al.|Movement Disorders|2013Cited by 158
Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson?s disease and related neurodegenerative disordersJiro Fukae, Nobutaka Hattori, Masashi Takanashi et al.|Acta Neuropathologica|2004Cited by 147
Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathologyNishant N. Vaikath, Omar M. A. El‐Agnaf, Nour K. Majbour et al.|Neurobiology of Disease|2015Cited by 144